Omeros (NASDAQ:OMER) Cut to “Sell” at StockNews.com

Omeros (NASDAQ:OMER) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday.

Omeros Trading Down 0.7 %

Shares of NASDAQ:OMER traded down $0.03 during midday trading on Tuesday, reaching $4.26. The company had a trading volume of 303,011 shares, compared to its average volume of 396,343. The company’s 50 day moving average price is $4.01 and its 200 day moving average price is $4.04. The stock has a market cap of $246.85 million, a P/E ratio of -1.81 and a beta of 1.47. Omeros has a 52-week low of $1.17 and a 52-week high of $5.68.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. SPC Financial Inc. purchased a new stake in Omeros in the third quarter worth $77,000. SG Americas Securities LLC purchased a new position in shares of Omeros in the third quarter worth about $80,000. Oppenheimer & Co. Inc. purchased a new position in shares of Omeros in the first quarter worth about $85,000. Comerica Bank raised its position in Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Omeros by 75.5% in the first quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 12,951 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.